Korro Bio, Inc. SEC filings KRRO
Korro Bio, Inc. has 830 filings in SEC EDGAR's recent list, going back to Apr 14, 2017. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (agreement ended, results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Apr 16, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 12, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 18, 2025 | Dec 31, 2024 |
| ARS | Annual report to shareholders | Apr 29, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 26, 2024 | Dec 31, 2023 |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 10, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 15, 2022 | Dec 31, 2021 |
| 10-K | Annual report | Mar 29, 2021 | Dec 31, 2020 |
| 10-K | Annual report | Mar 26, 2020 | Dec 31, 2019 |
Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KRRO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1703647
- Former names
- Frequency Therapeutics, Inc. (until Nov 6, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.